Cargando…

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is widely used in patients with type 2 diabetes. However, the pleiotropic effects of sitagliptin is not well understood. OBJECTIVE: To assess the clinical efficacy and safety of sitagliptin on atherosclerosis, β-cell function, and glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsurutani, Yuya, Omura, Masao, Matsuzawa, Yoko, Saito, Jun, Higa, Mariko, Taniyama, Matsuo, Nishikawa, Tetsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522982/ https://www.ncbi.nlm.nih.gov/pubmed/28761576 http://dx.doi.org/10.1016/j.curtheres.2016.12.002

Ejemplares similares

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
por: Florentin, Matilda, et al.
Publicado: (2022)

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
por: Masuda, Daisaku, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
por: Kubota, Yoshiaki, et al.
Publicado: (2012)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
por: Narayanan, Niya, et al.
Publicado: (2022)

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor
por: Maita, Hiroki, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
por: Komatsu, Tomohiro, et al.
Publicado: (2023)

Increased Serum Dihomo-γ-linolenic Acid Levels Are Associated with Obesity, Body Fat Accumulation, and Insulin Resistance in Japanese Patients with Type 2 Diabetes
por: Tsurutani, Yuya, et al.
Publicado: (2018)

Clinical Utility of the Adrenocorticotropin Stimulation Test with/without Dexamethasone Suppression for Definitive and Subtype Diagnosis of Primary Aldosteronism
por: Inoue, Kosuke, et al.
Publicado: (2017)

MON-215 Clinical Factors Associated with Insulin Secretion and Sensitivity in Patients with Primary Aldosteronism
por: Tsurutani, Yuya, et al.
Publicado: (2020)

MON-203 Aldosterone Biosynthesis Among Patients with Overt or Subclinical Cushing’s Syndrome
por: Inoue, Kosuke, et al.
Publicado: (2020)

Cortisol Co-Secretion and Clinical Usefulness of ACTH Stimulation Test in Primary Aldosteronism: A Systematic Review and Biases in Epidemiological Studies
por: Inoue, Kosuke, et al.
Publicado: (2021)

Association Between Aldosterone and Hypertension Among Patients With Overt and Subclinical Hypercortisolism
por: Inoue, Kosuke, et al.
Publicado: (2022)

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
por: Wilson, Jessica R, et al.
Publicado: (2020)

Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study
por: Arulmozhiraja, Sundaram, et al.
Publicado: (2016)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
por: Li, Jingjing, et al.
Publicado: (2014)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
por: Zheng, Wenbin, et al.
Publicado: (2018)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

FRI136 Adrenal Venous Sampling Criteria For Chemiluminescent Enzyme Immunoassay
por: Nakai, Kazuki, et al.
Publicado: (2023)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats
por: Rofaeil, Remon Roshdy, et al.
Publicado: (2022)

MON-622 Rapid Improvement in Glycated Albumin Before Educational Admission Predicts Fair Glycemic Control One Year After the Discharge of Patients with Type 2 Diabetes Mellitus
por: Katsuragawa, Sho, et al.
Publicado: (2020)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

A haplotype in the dipeptidyl peptidase 4 gene impacts glycemic-related traits of Brazilian older adults
por: Alves, E.S., et al.
Publicado: (2022)

Is it Possible to Extirpate Cardiovascular Events in Primary Aldosteronism After Surgical Treatment
por: Nishikawa, Tetsuo, et al.
Publicado: (2010)

Identification of Novel Human Dipeptidyl Peptidase-IV Inhibitors of Natural Origin (Part II): In Silico Prediction in Antidiabetic Extracts
por: Guasch, Laura, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Des-Fluoro-Sitagliptin Regulates Brown Adipose Tissue Uncoupling Protein Levels in Mice with Diet-Induced Obesity
por: Shimasaki, Takanobu, et al.
Publicado: (2013)

Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, examined in non‐obese diabetic mice
por: Tsuji, Takumi, et al.
Publicado: (2012)

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
por: Godinho, Ricardo, et al.
Publicado: (2015)

Antidiabetic activity of Commiphora mukul and Phyllanthus emblica and Computational analysis for the identification of active principles with dipeptidyl peptidase IV inhibitory activity
por: Mohanty, Ipseeta Ray, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vpk4mmil7kvldokjasad462tmt